Stock Market Reviews

PFSA (Profusa, Inc.) News

Get the latest news, insights, and market updates on PFSA (Profusa, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
  With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million BERKELEY, Calif, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces it
  Feb 19, 2026 - $PFSA
• Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
  Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to en
  Feb 13, 2026 - $PFSA
• Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
  Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to en
  Feb 12, 2026 - $PFSA
• Profusa Announces 1-for-75 Reverse Stock Split
  BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-seventy-five (1:75) reverse stock split of its common st
  Feb 5, 2026 - $PFSA
• Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
  Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the presentation of positive US-study clinical trial results at Leipzig Interventional Course in Leipgzig, Germany on Wednesday, Ja
  Jan 29, 2026 - $PFSA
• Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
  Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY, Calif, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the launch of its Health
  Jan 16, 2026 - $PFSA
• Profusa Adds Leading Greek Vascular Surgeon to Customer Base
  Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a collaboration with Theodosios Bisdas, M.D., Ph.D., FACS, Head of Clinic of Vascular Surgery,
  Jan 8, 2026 - $PFSA
• Profusa Bolsters European Commercial Network with New French Distributor, MedSell
  MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately 8% of all CLTI cases in France BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Profusa, I
  Dec 31, 2025 - $PFSA
• Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35
  New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from 33% to 50% BERKELEY, Calif, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the re
  Dec 30, 2025 - $PFSA
• Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025
  Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen BERKELEY, Calif, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s bioch
  Dec 15, 2025 - $PFSA